Major adverse cardiovascular events

Source: Wikipedia, the free encyclopedia.

Major adverse cardiovascular events (MACE, or major adverse cardiac events) is a composite endpoint frequently used in cardiovascular research.[1][2] Despite widespread use of the term in clinical trials, the definitions of MACE can differ, which makes comparison of similar studies difficult.[3]

Definition

The so-called "classical 3-point MACE" is defined as a composite of nonfatal

Heart Failure), ischemic cardiovascular [CV] events, cardiac death, or MACE".[6] Yet another study defined MACE as "CV death, hospitalization for HF, or myocardial infarction (MI)".[7]

The heterogeneity of the sets defining MACE, hampering systematic reviews and meta-analyses, has been repeatedly criticized.[8][9][10]

Risk factors for MACE

Which conditions are risk factors for MACE depends on some characteristics of the investigated cohort. Established risk indicators in the general population include age, pre-existing

HDL concentration and hypertension, as, e. g., demonstrated by the Framingham Heart Study. More recently, additional risk indicators have been identified, e. g. type 2 allostatic load,[11] high-sensitivity C-reactive protein, d-dimer level,[12] renal failure[13] and altered thyroid function.[14][15][16][17]

Therapeutic interventions

Two reviews have concluded that SGLT2 inhibitors benefit patients with atherosclerotic MACE.[18][19] One of those studies defined MACE as the composite of myocardial infarction, stroke, or cardiovascular death.[18] Other studies have shown MACE to be potently predicted by levels of ceramide found in patients.[20]


References